In a strategic move, Moria, an established leader in ophthalmic microsurgery instruments, has renewed its partnership with Naxicap Partners while also welcoming Eurazeo’s Nov Sant Actions Non Cotes Fund as a minority shareholder through a new leveraged buyout (LBO). Moria, founded in 1820, operates extensively in the ophthalmic surgery market with a diverse catalog of over 2,200 products. The company’s revenues have seen substantial growth from 30 million to 55 million euros following the initial LBO in 2019, driven by both organic growth and the acquisition of Italian company Alchimia. With 90% of its activities being international, the company seeks to expand its external growth strategy, particularly in the U.S. and Europe, and aims to double its activities by 2028. Eurazeo’s investment of 35 million euros, supported by new unitranche debt from Bridgepoint Credit, reflects confidence in Moria’s management and growth potential, positioning the company for further success and innovation in the global ophthalmic market.
Healthcare, Private Equity, Medical Devices,France, Global
https://www.eurazeo.com/en/newsroom/press-releases/eurazeo-new-shareholder-moria-alongside-its-historic-sponsor-naxicap